SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Möller Burkhard)
 

Sökning: WFRF:(Möller Burkhard) > Patient-Reported Ou...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006334naa a2200709 4500
001oai:lup.lub.lu.se:347a0403-784e-4c78-97ed-41ada68b000f
003SwePub
008240423s2024 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/347a0403-784e-4c78-97ed-41ada68b000f2 URI
0247 a https://doi.org/10.3899/jrheum.2023-07642 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Ørnbjerg, Lykke M.u Copenhagen University Hospital4 aut
2451 0a Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
264 1c 2024
300 a 12 s.
520 a Objective. To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods. Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results. For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion. In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex, and age at onset of disease were observed, emphasizing the potential influence of factors other than disease activity on PROs.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
653 a epidemiology
653 a fatigue
653 a pain
653 a psoriatic arthritis
653 a tumor necrosis factor inhibitors
7001 a Rugbjerg, Kathrineu Copenhagen University Hospital4 aut
7001 a Georgiadis, Stylianosu Copenhagen University Hospital4 aut
7001 a Rasmussen, Simon H.u Copenhagen University Hospital4 aut
7001 a Jacobsson, Lennartu University of Gothenburg,Sahlgrenska Academy4 aut
7001 a Loft, Anne G.u Aarhus University Hospital4 aut
7001 a Iannone, Florenzou University of Bari Aldo Moro4 aut
7001 a Fagerli, Karen M.u Diakonhjemmet Hospital4 aut
7001 a Vencovsky, Jiriu Charles University in Prague4 aut
7001 a Santos, Maria J.u Hospital Garcia de Orta4 aut
7001 a Möller, Burkhardu Bern University Hospital4 aut
7001 a Pombo-Suarez, Manuelu Complejo Hospitalario Universitario de Santiago4 aut
7001 a Rotar, Zigau University of Ljubljana,University Medical Centre Ljubljana4 aut
7001 a Gudbjornsson, Bjornu National University Hospital of Iceland4 aut
7001 a Cefle, Ayseu Kocaeli University4 aut
7001 a Eklund, Kariu Helsinki University Central Hospital4 aut
7001 a Codreanu, Catalinu Carol Davila University of Medicine and Pharmacy4 aut
7001 a Jones, Gareth4 aut
7001 a van der Sande, Marleenu University of Amsterdam4 aut
7001 a Wallman, Johan K.u Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)med-jnk
7001 a Sebastiani, Marcou University of Modena and Reggio Emilia4 aut
7001 a Michelsen, Brigitteu Diakonhjemmet Hospital,Sørlandet Hospital,Copenhagen University Hospital4 aut
7001 a Závada, Jakubu Charles University in Prague4 aut
7001 a Nissen, Michael J.u Geneva University Hospital4 aut
7001 a Sanchez-Piedra, Carlosu Carlos III Health Institute4 aut
7001 a Tomšič, Matijau University Medical Centre Ljubljana,University of Ljubljana4 aut
7001 a Love, Thorvardur J.u University of Iceland4 aut
7001 a Relas, Heikkiu Helsinki University Central Hospital4 aut
7001 a Mogosan, Corinau Carol Davila University of Medicine and Pharmacy4 aut
7001 a Hetland, Merete L.u Copenhagen University Hospital,University of Copenhagen4 aut
7001 a Østergaard, Mikkelu University of Copenhagen,Copenhagen University Hospital4 aut
7102 a University of Gothenburgb Copenhagen University Hospital4 org
7730 t Journal of Rheumatologyg 51:4, s. 378-389q 51:4<378-389x 0315-162X
8564 u http://dx.doi.org/10.3899/jrheum.2023-0764x freey FULLTEXT
8564 8u https://lup.lub.lu.se/record/347a0403-784e-4c78-97ed-41ada68b000f
8564 8u https://doi.org/10.3899/jrheum.2023-0764

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy